Posted by Michael Wonder on 03 Mar 2022
Criticism of study planning: patient-reported endpoints are often collected far too briefly
3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side effects impair the early benefit assessment.
Abemaciclib in combination with fulvestrant is used to treat post-menopausal women with hormone receptor-positive, HER2 negative locally advanced or metastatic breast cancer. After the expiry of a decision by the Federal Joint Committee (G-BA), the IQWiG has again assessed its additional benefit - with mixed results.
